Metabolism of CDRI-85/92, a new potent anti-ulcer agent, involving cis-trans conversion.

@article{Srivastava2004MetabolismOC,
  title={Metabolism of CDRI-85/92, a new potent anti-ulcer agent, involving cis-trans conversion.},
  author={Pratima Srivastava and Preeti Sharma and Jawahar Lal and Dinesh Kumar Dikshit and Kunnath Padamnabham Madhusudanan and Ram Chandra Gupta},
  journal={Drug metabolism and drug interactions},
  year={2004},
  volume={20 1-2},
  pages={57-75}
}
CDRI 85/92, an anti-ulcer drug, is a new proton pump inhibitor, currently in an advanced stage of drug development. To know more about the drug it was our objective to delineate/identify the metabolic pathway as well as the enzymes responsible for the formation of metabolites. Metabolism of CDRI-85/92 (cis-5-styryl-2-oxazolidinone-4-carboxylic acid) was… CONTINUE READING